Authors

Latest:

Dr Atkins on the Rationale of Investigating Nivolumab/Ipilimumab in RCC

Michael B. Atkins, MD, discusses the rationale for launching the phase 2 HCRN GU16-260 trial in patients with advanced renal cell carcinoma.

Ruby Arora, MD

Ruby Arora, MD, is a resident physician of internal medicine in the Department of Medicine at the University of Illinois College of Medicine.

Latest:

Dr Arora on the Declining Incidence of MCL in the United States

Ruby Arora, MD, discusses the declining incidence of MCL in the US, as well as ways to address disparities that remain in MCL management.

Mark Alwardt

Latest:

Oral Oncolytics Will Require Health Care System to Adapt

Judging from the drug pipeline, the future of oncology is oral chemotherapy.

Allison A. DiPasquale, MD

Latest:

Dr DiPasquale on the Continued Investigation into Cerianna PET Scans in Breast Cancer

Allison A. DiPasquale, MD, discusses the continued evaluation of Cerianna positron emission tomography scans in patients with breast cancer and highlights the need for a multidisciplinary approach when treating patients in this population.

Ricardo Costa, MD, MSc

Latest:

Dr. Costa on the Implications of the KEYNOTE-522 Trial in TNBC

Ricardo Costa, MD, MSC, discusses the implications of the phase 3 KEYNOTE-522 trial trial in patients with high-risk, early-stage triple-negative breast cancer.

Stephen Hursting, PhD, MPH

Latest:

Dr Hursting on Weight Loss Drugs and the Potential to Reduce Obesity-Related Breast Cancer

R. Tyler Hillman, MD, PhD

R. Tyler Hillman, MD, PhD, is assistant professor in the Department of Gynecologic Oncology and Reproductive Medicine of the Division of Surgery at The University of Texas MD Anderson Cancer.

Latest:

Dr Hillman on Identifying New Therapy Candidates in Adult-Type Granulosa Cell Tumor

R. Tyler Hillman, MD, PhD, discusses ways of identifying new drug therapy candidates in patients with adult-type granulosa cell tumor of the ovary.

Charles A. Powell, MD, MBA, Mount Sinai-National Jewish Health Respiratory Institute

Latest:

Monitoring Patients for Interstitial Lung Disease

Experts discuss the optimal monitoring of patients to identify interstitial lung disease early and how to intervene.

Katie Kelley, MD

Latest:

Patient Profile 3: Advanced HCC Treated With Cabozantinib in Second Line

Centering discussion on the final patient profile, panelists consider how they select optimal therapy in the second-line setting of advanced hepatocellular carcinoma.

Cheryl Saenz, MD

Latest:

Dr. Saenz on the Need for Ongoing Research Efforts in Cervical Cancer

Cheryl Saenz, MD, discusses the need for ongoing research efforts in cervical cancer.

Huma Q. Rana, MD, MPH

Latest:

Dr. Rana on Using Age at Diagnosis to Guide the Utility of Genetic Testing in Prostate Cancer

Huma Q. Rana, MD, MPH, discusses the use of age at diagnosis to guide the utility of genetic testing in men with prostate cancer.

Devon Womack

Latest:

Providing Timely Cancer Care Access Is Crucial Amid Growing Patient Volume

A closer look at some of the approaches being used across The US Oncology Network to improve patient access can provide helpful insight into how practices can meet the growing need for their services.

Hannah Walker-Mimms, MS

Latest:

Dr Walker-Mimms on Outcomes With Filanesib in Ewing and Clear Cell Sarcoma

Hannah Walker-Mimms, MS, discusses a study revealing that Ewing and clear cell sarcomas have increased sensitivity to filanesib over other cancer types.

Gautam Borthakur, MD

Latest:

Dr Borthakur on the SELECT MDS-1 Trial in Newly Diagnosed MDS

Gautam Borthakur, MD, discusses the ongoing phase 3 SELECT MDS-1 trial in patients with newly diagnosed myelodysplastic syndromes.

Akash Mukherjee, MD

Latest:

Current Treatment Perspectives for CAR T-Cell Therapy in R/R B-Cell Lymphoma

Chimeric antigen receptor T-cell therapy has proven to be an effective adoptive cellular therapy against relapsed/refractory B-cell lymphoma.

Sandra Mazzoni, DO

Latest:

Real-world Outcomes with Talquetamab

Panelists discuss how they manage talquetamab-specific toxicities including dysgeusia and nail/skin changes through patient preparation, dietary modifications with umami-rich foods, emollients, and extended dosing intervals.

UW School of Medicine

Latest:

UW Carbone Cancer Center Receives SPORE Designation, Federal Grant to Support Prostate Cancer Research

University of Wisconsin Carbone Cancer Center will be designated as a Specialized Program of Research Excellence, or SPORE, by the National Cancer Institute for research initiatives to advance new prostate cancer treatments.

Kate Baker, MD, MMHC

Kate Baker, MD, MMHC, is medical director of value-based care at Tennessee Oncology

Sally Lau, MD

Latest:

Dr Lau on Tarlatamab as Maintenance Therapy in Extensive-Stage SCLC

Sally Lau, MD, discusses the addition of tarlatamab to a PD-L1 inhibitor as first-line maintenance therapy for extensive-stage small cell lung cancer.

Nasser Khaled Altorki, MD

Latest:

Dr. Altorki on the Results of Post-Hoc Analyses of the IMpower010 Trial in NSCLC

Nasser Khaled Altorki, MD, discusses the results of post-hoc analyses of the phase 3 IMpower010 trial in non–small cell lung cancer.